Literature DB >> 16631340

Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia.

Kristen Kreisel1, Kristina Boyd, Patricia Langenberg, Mary-Claire Roghmann.   

Abstract

Recurrence is a common complication of Staphylococcus aureus infections. A shorter duration of antibiotic treatment for a S. aureus infection has been previously suggested as a possible risk factor for recurrence. We conducted a retrospective cohort study of patients with S. aureus infection complicated by bacteremia who survived their initial treatment (N = 397) at the VA Maryland Health Care System from 1995 to 2004 to determine if 2 weeks or less of antibiotic therapy is significantly associated with a higher rate of recurrence. Recurrence was defined as recurrence of infection because of S. aureus with the same susceptibility to methicillin within 1 year of treatment of the initial bacteremia. Seventeen percent of patients who survived their initial infection had a recurrence of infection. Mean duration of antibiotic therapy in those who recurred was longer than in those who did not recur (21 versus 18 days, P = .18). No evidence was found to support an association between a duration of therapy of 14 days or less and an increased risk for recurrence (RR, 0.68; 95% CI, 0.44-1.04). However, being HIV infected (OR, 4.59; 95% CI, 1.61-13.10), having diabetes (OR, 2.02; 95% CI, 1.13-3.61) and having an infection due to a methicillin-resistant S. aureus (MRSA) (OR, 2.11; 95% CI, 1.17-3.80) were independent risk factors for recurrence. In conclusion, 2 weeks or less of antibiotic therapy was not associated with an increased risk for recurrence. However, patients with diabetes or HIV infection and patients with MRSA infections are at an increased risk for recurrence and should be followed more closely.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631340     DOI: 10.1016/j.diagmicrobio.2006.01.021

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  22 in total

1.  Surveillance and management of all types of Staphylococcus aureus bacteraemia.

Authors:  John Paul
Journal:  BMJ       Date:  2006-08-05

2.  High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Ya-Chi Ho; Shan-Chwen Chang; Su-Ru Lin; Wei-Kung Wang
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

3.  Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections.

Authors:  M Michalia; M Kompoti; A Koutsikou; A Paridou; P Giannopoulou; E Trikka-Graphakos; P Clouva-Molyvdas
Journal:  Intensive Care Med       Date:  2008-09-20       Impact factor: 17.440

4.  Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.

Authors:  Yong Pil Chong; Song Mi Moon; Kyung-Mi Bang; Hyun Jung Park; So-Youn Park; Mi-Na Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

5.  Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.

Authors:  Z A Kanafani; W M Kourany; V G Fowler; D P Levine; G A Vigliani; M Campion; D E Katz; G R Corey; H W Boucher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12       Impact factor: 3.267

6.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.

Authors:  A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert
Journal:  Infection       Date:  2013-03-29       Impact factor: 3.553

7.  Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.

Authors:  Karoline Sidelmann Brinch; Anne Sandberg; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

8.  Biosynthesis of staphylococcal enterotoxin A by genetic engineering technology and determination of staphylococcal enterotoxin A in water by HPLC-ESI-TOF.

Authors:  Hong-Na Li; Fei Yuan; Yun-Jing Luo; Jian-Feng Wang; Chuan-Bin Zhang; Wei-E Zhou; Zhi-Qin Ren; Wen-Jie Wu; Feng Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-04       Impact factor: 4.223

9.  The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era.

Authors:  M D Burkey; L E Wilson; R D Moore; G M Lucas; J Francis; K A Gebo
Journal:  HIV Med       Date:  2008-08-21       Impact factor: 3.180

10.  The human nasal microbiota and Staphylococcus aureus carriage.

Authors:  Daniel N Frank; Leah M Feazel; Mary T Bessesen; Connie S Price; Edward N Janoff; Norman R Pace
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.